Tirzepatida: State of the Art (2026)

Instagram:⁠ ⁠@dr.gilbertogarciabernal⁠⁠Infografías en X:⁠ ⁠@DoctorGilbertoG⁠Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial (Diabetes Care, 2026)GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis (Metabolism, 2026)Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. SURPASS-CVOT (NEJM, 2025) Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic (Diabetes Obes Metab, 2025)Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes (Diabetes Ther, 2025)Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial (Lancet, 2025)Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial (Obesity, 2025)Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol (BMJ Open, 2025)Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting (Diabetes Obes Metab, 2025) Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. SURMOUNT-5 (NEJM, 2025) An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists (JACC Adv, 2025)Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. SURMOUNT-OSA (NEJM, 2024) The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (J Endocrinol Invest, 2024)Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. SYNERGY-NASH (NEJM, 2024) Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (JAMA Intern Med, 2024)Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2024)Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis (Front Endocrinol, 2023)Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial (Nat Med, 2023)Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial (JAMA, 2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (Lancet, 2023)Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1 (NEJM, 2022)Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (JAMA, 2022) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (Lancet, 2021)Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (Lancet, 2021)Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. SURPASS-2 (NEJM, 2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)